| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.AUTREV.2011.06.011 |
| P698 | PubMed publication ID | 21958603 |
| P2093 | author name string | J W J Bijlsma | |
| M Bijl | |||
| J Tekstra | |||
| K M A C Luijten | |||
| P433 | issue | 5 | |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| P304 | page(s) | 326-329 | |
| P577 | publication date | 2011-09-18 | |
| P1433 | published in | Autoimmunity Reviews | Q15754966 |
| P1476 | title | The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment | |
| P478 | volume | 11 |
| Q46055629 | A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). |
| Q40947347 | Aberrant expression of regulatory cytokine IL-35 in patients with systemic lupus erythematosus |
| Q27021623 | Approaches for estimating minimal clinically important differences in systemic lupus erythematosus |
| Q38097129 | B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design |
| Q38014539 | Belimumab for the management of systemic lupus erythematosus |
| Q38810737 | Belimumab in the management of systemic lupus erythematosus - an update |
| Q90354917 | Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus |
| Q46803412 | Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index |
| Q35031692 | Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis. |
| Q37069721 | Evaluation of Endothelial Cell Adhesion Molecules and Anti-C1q Antibody in Discriminating between Active and Non-Active Systemic Lupus Erythematosus |
| Q44750823 | Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus |
| Q34430439 | Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study. |
| Q37227144 | Genetic risk and longitudinal disease activity in systemic lupus erythematosus using targeted maximum likelihood estimation. |
| Q47346411 | Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients. |
| Q38095888 | Is there a cure for systemic lupus erythematosus? |
| Q26822662 | Linking susceptibility genes and pathogenesis mechanisms using mouse models of systemic lupus erythematosus |
| Q36554724 | Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group repor |
| Q26827651 | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report |
| Q37591123 | Non-pathogenic tissue-resident CD8+ T cells uniquely accumulate in the brains of lupus-prone mice |
| Q30391564 | Patient-reported outcomes in lupus clinical trials with biologics. |
| Q91282440 | Precision medicine in lupus nephritis: can biomarkers get us there? |
| Q35229292 | Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments |
| Q38149960 | Promising biomarkers for systemic lupus erythematosus |
| Q61821116 | Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus |
| Q35960478 | Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study |
| Q36758822 | The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis |
| Q40002833 | The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis |
| Q38258871 | Update on belimumab for the management of systemic lupus erythematosus |
Search more.